A stock’s 52-week high and low prices can offer a wealth of information about its current standing and prospective future performance. Recursion Pharmaceuticals Inc’s current trading price is -54.05% away from its 52-week high, while its distance from the 52-week low is 49.87%. The stock’s price range for this time frame has been between $3.79 and $12.36. The trading volume of the company’s shares in the Healthcare reached around 17.9 million for the day, which was evidently lower than the average daily volume of 28.39 million over the last three months.
The current stock price for Recursion Pharmaceuticals Inc (RXRX) is $5.68. The stock experienced a significant increase during the last trading session, reaching $10.0 after opening at $5.68. It dipped to a low of $4.0 before ultimately closing at $5.95.
Recursion Pharmaceuticals Inc’s stock has seen a rocky market performance.
How Financial Performance Impacts Market Capitalization
Recursion Pharmaceuticals Inc (RXRX) has experienced a quarterly rise of 3.27% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 2.45B.
Decoding Analysts’ Ratings for Recursion Pharmaceuticals Inc
As of right now, 1 analyst is rating Recursion Pharmaceuticals Inc as a BUY, 1 of the polled analysts branded the stock as an OVERWEIGHT, 6 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 5.30, with a change in price of -0.45. Similarly, Recursion Pharmaceuticals Inc recorded 25,219,182 in trading volume during the last 100 days, posting a change of -7.34%.
How RXRX’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for RXRX stands at 0.10. Similarly, the long-term debt-to-equity ratio is also 0.08.
RXRX Stock Stochastic Average
The raw stochastic average for Recursion Pharmaceuticals Inc over the last 50 days is presently at 53.92%. This reflects a surge from the raw stochastic average of the previous 20 days, which was noted at 37.45%. Further, the company’s Stochastic %K and %D values for the last 20 days were 43.12% and 47.38%, respectively.
RXRX Stock Price Performance Analysis
A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. The metric has seen a significant loss of -28.55% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -26.14%. Over the past 30 days, the price of RXRX has fallen by 9.02%. And in the last five days, it has fallen by -12.48%.
